ADMA Biologics (NASDAQ:ADMA) Stock Price Breaks Below 200-Day Moving Average – Time to Sell?

ADMA Biologics Inc (NASDAQ:ADMA) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $10.93 and traded as low as $10.25. ADMA Biologics shares last traded at $10.48, with a volume of 13,368,485 shares trading hands.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Q3 revenue was $141.1 million, ahead of the $138.1 million consensus, while GAAP EPS was $0.22 and adjusted EPS was $0.23—both above estimates. GAAP net income rose 37% year over year to $49.9 million. ADMA Q3 results and business update
• Positive Sentiment: ASCENIV revenue increased 31% year over year to $124.7 million. Gross margin expanded by about 1,450 basis points to 71%, and adjusted EBITDA grew 32% to $77.3 million, indicating improving profitability and operating leverage. ADMA Q3 results and business update
• Positive Sentiment: The company increased its adjusted earnings outlook, cited encouraging regulatory feedback for SG-001, and highlighted share repurchases and evidence supporting ASCENIV’s commercial position. ADMA Q3 results and business update
• Neutral Sentiment: ADMA reiterated its FY2026 revenue guidance rather than raising it. Revenue grew 5% year over year, a more modest rate than ASCENIV’s growth; these factors may have tempered the upbeat earnings report, though the provided articles do not establish why the stock fell. ADMA Q3 results and business update

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ADMA. Zacks Research raised shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Mizuho reduced their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

ADMA Biologics Price Performance

The stock has a market cap of $2.35 billion, a price-to-earnings ratio of 14.97 and a beta of 0.65. The company has a 50 day simple moving average of $10.07 and a 200-day simple moving average of $10.93. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm had revenue of $141.10 million for the quarter, compared to analyst estimates of $138.11 million. During the same period in the previous year, the business earned $0.15 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. Research analysts expect that ADMA Biologics Inc will post 0.78 EPS for the current year.

Hedge Funds Weigh In On ADMA Biologics

Several large investors have recently modified their holdings of ADMA. Lido Advisors LLC boosted its holdings in shares of ADMA Biologics by 35.3% during the third quarter. Lido Advisors LLC now owns 32,699 shares of the biotechnology company’s stock worth $328,000 after acquiring an additional 8,525 shares during the period. Fulcrum Asset Management LLP grew its position in shares of ADMA Biologics by 1,306.3% in the third quarter. Fulcrum Asset Management LLP now owns 14,963 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 13,899 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of ADMA Biologics by 4.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 32,087 shares of the biotechnology company’s stock valued at $319,000 after purchasing an additional 1,316 shares during the last quarter. Ethic Inc. acquired a new position in shares of ADMA Biologics in the third quarter valued at approximately $131,000. Finally, Alps Advisors Inc. increased its stake in shares of ADMA Biologics by 91.5% during the third quarter. Alps Advisors Inc. now owns 63,495 shares of the biotechnology company’s stock worth $637,000 after purchasing an additional 30,331 shares during the period. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.